DaVita Inc. $DVA Shares Sold by Empowered Funds LLC

Key Points

• Empowered Funds LLC cut its DaVita stake by 85.7% in the first quarter, selling 19,673 shares and retaining 3,293 shares valued at approximately $506,000.
• Other institutional investors increased their positions, including Arrowstreet Capital, Norges Bank and Corient Private Wealth; institutional investors collectively own 90.12% of DaVita.
• DaVita exceeded quarterly earnings and revenue expectations, reporting $4.02 in EPS and $3.55 billion in revenue. Despite this, analysts maintain a consensus “Hold” rating with a $221.75 price target, while shares opened at $178.25.

Empowered Funds LLC trimmed its stake in DaVita Inc. (NYSE:DVA - Free Report) by 85.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,293 shares of the company's stock after selling 19,673 shares during the quarter. Empowered Funds LLC's holdings in DaVita were worth $506,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership boosted its holdings in DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company's stock valued at $135,196,000 after acquiring an additional 636,191 shares during the last quarter. Norges Bank purchased a new stake in shares of DaVita during the 4th quarter worth about $49,164,000. Corient Private Wealth LLC increased its position in DaVita by 1,493.1% during the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company's stock worth $40,706,000 after purchasing an additional 335,809 shares in the last quarter. Man Group plc raised its holdings in DaVita by 1,608.6% in the second quarter. Man Group plc now owns 285,809 shares of the company's stock valued at $40,713,000 after buying an additional 269,081 shares during the period. Finally, Voloridge Investment Management LLC lifted its position in DaVita by 2,905.7% during the third quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company's stock valued at $30,324,000 after buying an additional 220,628 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on DVA shares. Barclays raised their target price on shares of DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 5th. Zacks Research downgraded DaVita from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. Weiss Ratings raised DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 5th. Truist Financial reduced their price objective on DaVita from $250.00 to $215.00 and set a "hold" rating on the stock in a research note on Friday, August 7th. Finally, Raymond James Financial set a $220.00 target price on DaVita in a research report on Friday. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $221.75.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares of the company's stock, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is currently owned by insiders.

DaVita Stock Down 3.0%

Shares of NYSE DVA opened at $178.25 on Wednesday. The stock's 50 day moving average price is $218.11 and its two-hundred day moving average price is $178.10. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49. The stock has a market capitalization of $11.37 billion, a P/E ratio of 14.59, a PEG ratio of 0.61 and a beta of 0.88.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts' consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. During the same period in the previous year, the business earned $2.95 EPS. The business's quarterly revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.

DaVita Company Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source